SELLAS Life Sciences Group, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $49.00K, a 81.72% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $21.00K, a 97.74% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for fiscal 2023 was $289.00K, a 72.42% decline from fiscal 2022.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for fiscal 2022 was $1.05M, a 65.85% decline from fiscal 2021.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for fiscal 2021 was $3.07M, a 64.42% decline from fiscal 2020.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, new issues for fiscal 2020 was $8.63M, a 135.78% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-03-31 | $49.00K 10-Q · filed 2025-05-13 | $70.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $289.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.20M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.27M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $268.00K 10-Q · filed 2024-05-14 | $1.32M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $929.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.05M 10-K · filed 2024-03-28 |
| 2022-09-30 | $69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $50.00K 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $3.07M 10-K · filed 2023-03-16 |
| 2021-09-30 | $2.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $17.00K 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $3.00M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $8.63M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $3.66M 10-K · filed 2021-03-23 |
| 2019-09-30 | $383.00K 10-Q · filed 2019-11-14 | -$8.26M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-06-30 | $1.04M 10-Q · filed 2020-08-13 | $3.27M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $2.23M 10-Q · filed 2019-05-15 | $6.55M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-12-31 | -$11.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $9.65M 10-K · filed 2020-03-13 |
| 2018-09-30 | $11.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | |
| 2018-06-30 | $4.32M 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $5.33M 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $6.01M 10-K · filed 2019-03-22 | |
| 2016-12-31 | $33.53M 10-K · filed 2017-03-15 | |
| 2015-12-31 | $47.42M 10-K · filed 2017-03-15 | |
| 2014-12-31 | $10.71M 10-K · filed 2017-03-15 | |
| 2013-12-31 | $19.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2016-04-15 | $37.54M 10-K/A · filed 2016-04-15 |
| 2012-12-31 | $36.38M 8-K · filed 2015-12-04 | |
| 2011-12-31 | $18.61M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |